Strs Ohio Makes New Investment in TG Therapeutics, Inc. $TGTX

Strs Ohio purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,900 shares of the biopharmaceutical company’s stock, valued at approximately $785,000.

Several other institutional investors have also recently added to or reduced their stakes in TGTX. NBC Securities Inc. boosted its position in shares of TG Therapeutics by 82,300.0% in the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 823 shares during the last quarter. Golden State Wealth Management LLC lifted its stake in shares of TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 433 shares in the last quarter. SVB Wealth LLC acquired a new position in TG Therapeutics during the 1st quarter worth approximately $37,000. Vermillion Wealth Management Inc. purchased a new position in shares of TG Therapeutics in the fourth quarter valued at $30,000. Finally, USA Financial Formulas acquired a new stake in shares of TG Therapeutics during the first quarter valued at about $57,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Trading Down 0.7%

TG Therapeutics stock opened at $32.37 on Friday. TG Therapeutics, Inc. has a 52 week low of $21.16 and a 52 week high of $46.48. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The firm has a market capitalization of $5.14 billion, a price-to-earnings ratio of 87.49 and a beta of 1.88. The company has a 50 day moving average price of $31.91 and a 200 day moving average price of $35.65.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). The business had revenue of $141.15 million during the quarter, compared to analysts’ expectations of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. TG Therapeutics’s revenue for the quarter was up 92.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. Research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director owned 94,061 shares of the company’s stock, valued at $3,032,526.64. This trade represents a 18.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 10.64% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 target price for the company in a research report on Thursday, July 10th. B. Riley upped their price objective on TG Therapeutics from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.00.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.